Show simple item record

AuthorYounis, Nour K.
AuthorZareef, Rana O.
AuthorFakhri, Ghina
AuthorBitar, Fadi
AuthorEid, Ali H.
AuthorArabi, Mariam
Available date2023-03-30T10:12:59Z
Publication Date2021-12-01
Publication NamePharmacological Reports
Identifierhttp://dx.doi.org/10.1007/s43440-021-00316-1
CitationYounis, N.K., Zareef, R.O., Fakhri, G. et al. COVID-19: potential therapeutics for pediatric patients. Pharmacol. Rep 73, 1520–1538 (2021). https://doi.org/10.1007/s43440-021-00316-1
ISSN1734-1140
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85113784757&origin=inward
URIhttp://hdl.handle.net/10576/41537
AbstractThe global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and complicated COVID-19. Supportive treatment is recommended in all patients. Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease. Up till now, remdesivir is the only USFDA-approved anti-COVID-19 medication indicated in the majority of symptomatic patients with moderate to severe disease. Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support. The use of these medications in pediatric patients is founded on evidence deriving from adult studies. No randomized controlled trials (RCTs) involving pediatric COVID-19 patients have assessed these medications’ efficacy and safety, among others. Similarly, three novel monoclonal anti-SARS-CoV-2 spike protein antibodies, bamlanivimab, casirivimab and imdevimab, have been recently authorized by the USFDA. Nonetheless, their efficacy has not been demonstrated by multiple RCTs. In this review, we aim to dissect the various potential therapeutics used in children with COVID-19. We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics. Our review offers an efficient and practical guide for treating children with COVID-19.
SponsorOpen access funding provided by the Qatar National Library.
Languageen
PublisherSpringer
SubjectCOVID-19
Pediatric patients
SARS-CoV-2
Therapeutics
TitleCOVID-19: potential therapeutics for pediatric patients
TypeArticle Review
Issue Number6
Volume Number73
ESSN2299-5684
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record